Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | HTR1F | P30939 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889787 | 0.87 | HTR6 (0.61) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3886084 | 0.84 | HTR6 (0.52) | HTR6PPARGPPARDPPARAHTR1A | |
| SCHEMBL5657285 | 0.81 | HTR6 (0.51) | HTR6PPARGPPARDPPARAHTR1A | |
| SCHEMBL13686068 | 0.80 | HTR6 (0.46) | HTR6PPARGPPARDPPARAHTR1A | |
| SCHEMBL3893883 | 0.79 | HTR6 (0.64) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL19971345 | 0.77 | IDE (0.43) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL28207563 | 0.75 | IDE (0.42) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL28857516 | 0.74 | IDE (0.41) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL19971445 | 0.74 | RORC (0.48) | HTR6DRD2 | |
| SCHEMBL3035292 | 0.71 | PPARG (0.82) | HTR6PPARGPPARDPPARAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456206-B1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885PPARG 3699/4885PPARD 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.